← Leaderboards
Tanya I Stoyanova
University Of California Los Angeles
$7,579,166
Attributed
$7,579,166
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,579,166 · 7
By mechanism
R01$4,252,587 · 3
R37$2,160,463 · 1
R00$728,807 · 1
K99$277,722 · 1
R03$159,587 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Owen N Witte$15,146,055
- David Mulholland$3,108,167
- Richard Staba$6,894,321
- Denise R Aberle$7,414,266
- Robert E Reiter$11,316,970
Others in their field
Top investigators on “Growth”
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$233,131,631
- Albert Lazzarini · California Institute Of Technology$170,110,000
- David H Reitze · University Of Florida$170,110,000
- Garret A Fitzgerald · University Of Pennsylvania$153,184,124
- David Heimbrook · Leidos Biomedical Research, Inc.$143,966,408
- Carol Nesel · Westat$116,355,411
Research focus
GrowthTherapeutic TargetMalignant Neoplasm Of ProstateMolecularInsightNovel Therapeutic InterventionSignal TransductionAndrogen Deprivation TherapyHormone TherapyOverexpressionUnited StatesTumor GrowthCessation Of LifePathway InteractionsAdvanced DevelopmentMortalityAdvanced DiseaseCellsTumorAggressive Clinical CourseAndrogensNeoplasm MetastasisAdvanced Prostate CancerNeurosecretory Systems
Grant awards (24)
Testing ATAD2 as a new therapeutic target for advanced prostate cancer$548,333
R01 · FY2025 · CA · contact PI
Delineate the Role of GSTP1 in Advanced Prostate Cancer$452,888
R01 · FY2025 · CA · contact PI
Elucidating the Role of Trop2 in Prostate Cancer$360,059
R37 · FY2025 · CA · contact PI
Testing ATAD2 as a new therapeutic target for advanced prostate cancer$562,551
R01 · FY2024 · CA · contact PI
Delineate the Role of GSTP1 in Advanced Prostate Cancer$426,489
R01 · FY2024 · CA · contact PI
Elucidating the Role of Trop2 in Prostate Cancer$342,914
R37 · FY2024 · CA · contact PI
Elucidating the Role of UCHL1 in Aggressive Prostate Cancer$321,910
R01 · FY2024 · CA · contact PI
Delineate the Role of GSTP1 in Advanced Prostate Cancer$467,334
R01 · FY2023 · CA · contact PI
Elucidating the Role of Trop2 in Prostate Cancer$352,304
R37 · FY2023 · CA · contact PI
Elucidating the Role of UCHL1 in Aggressive Prostate Cancer$349,830
R01 · FY2023 · CA · contact PI
Elucidating the Role of Trop2 in Prostate Cancer$364,090
R37 · FY2022 · CA · contact PI
Elucidating the Role of UCHL1 in Aggressive Prostate Cancer$210,004
R01 · FY2022 · CA · contact PI
Elucidating the Role of UCHL1 in Aggressive Prostate Cancer$162,061
R01 · FY2022 · CA · contact PI
Elucidating the Role of UCHL1 in Aggressive Prostate Cancer$374,240
R01 · FY2021 · CA · contact PI
Elucidating the Role of Trop2 in Prostate Cancer$366,134
R37 · FY2021 · CA · contact PI
Elucidating the Role of UCHL1 in Aggressive Prostate Cancer$376,947
R01 · FY2020 · CA · contact PI
Elucidating the Role of Trop2 in Prostate Cancer$374,962
R37 · FY2020 · CA · contact PI
Elucidating Novel Mechanisms Underlying Prostate Cancer Development$79,813
R03 · FY2019 · CA · contact PI
Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets$236,811
R00 · FY2018 · CA · contact PI
Elucidating Novel Mechanisms Underlying Prostate Cancer Development$79,774
R03 · FY2018 · CA · contact PI
Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets$242,996
R00 · FY2017 · CA · contact PI
Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets$249,000
R00 · FY2016 · CA · contact PI
Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets$138,861
K99 · FY2015 · CA · contact PI
Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets$138,861
K99 · FY2014 · CA · contact PI